

Activation of the unfolded protein response enhances motor recovery after spinal cord injury

V Valenzuela^{1,2,3}, E Collyer², D Armentano⁴, GB Parsons⁴, FA Court^{*,2,5} and C Hetz^{*1,3,5,6}

Spinal cord injury (SCI) is a major cause of paralysis, and involves multiple cellular and tissular responses including demyelination, inflammation, cell death and axonal degeneration. Recent evidence suggests that perturbation on the homeostasis of the endoplasmic reticulum (ER) is observed in different SCI models; however, the functional contribution of this pathway to this pathology is not known. Here we demonstrate that SCI triggers a fast ER stress reaction (1–3 h) involving the upregulation of key components of the unfolded protein response (UPR), a process that propagates through the spinal cord. Ablation of X-box-binding protein 1 (XBP1) or activating transcription factor 4 (ATF4) expression, two major UPR transcription factors, leads to a reduced locomotor recovery after experimental SCI. The effects of UPR inactivation were associated with a significant increase in the number of damaged axons and reduced amount of oligodendrocytes surrounding the injury zone. In addition, altered microglial activation and pro-inflammatory cytokine expression were observed in ATF4 deficient mice after SCI. Local expression of active XBP1 into the spinal cord using adeno-associated viruses enhanced locomotor recovery after SCI, and was associated with an increased number of oligodendrocytes. Altogether, our results demonstrate a functional role of the UPR in SCI, offering novel therapeutic targets to treat this invalidating condition.

Cell Death and Disease (2012) 3, e272; doi:10.1038/cddis.2012.8; published online 16 February 2012

Subject Category: Neuroscience

Spinal cord injury (SCI) due to mechanical trauma, ischemia, or tumor invasion leads to invalidating locomotor impairment. SCI often affects individuals in their productive age, having an enormous social and economic impact. The contribution of the various subcellular compartments to the process of tissue damage triggered by SCI has not been clearly elucidated. A number of pathological conditions affecting the nervous system, including SCI, can interfere with the function of a specific subcellular organelle, the endoplasmic reticulum (ER), resulting in a cellular condition termed ER stress.^{1,2} To alleviate ER stress, cells activate an integrated signaling pathway known as the unfolded protein response (UPR), which reestablish homeostasis by decreasing the extent of protein misfolding.² Conversely, chronic or irreversible ER stress triggers apoptosis to eliminate nonfunctional cells.³

The UPR is initiated by several stress sensors, including inositol-requiring enzyme-1 (IRE1) α , which is a kinase and endoribonuclease that upon activation, initiates the splicing of the mRNA encoding the transcriptional factor X-box-binding

protein 1 (XBP1),^{2,4} converting it into a potent activator of multiple UPR-responsive genes (termed XBP1s). XBP1s controls the expression of genes involved in protein folding, secretion, and protein quality control.⁵ IRE1 α also regulates other signaling events including the activation of JNK (c-Jun N-terminal kinases), modulating apoptosis and autophagy levels, in addition to degrading a subset of mRNA through its RNase activity (reviewed in Hetz²). Other important UPR effects are mediated by the stress sensor PKR-like endoplasmic reticulum kinase (PERK), which phosphorylates the eukaryotic translation initiation factor 2 α (eIF2 α), inhibiting protein translation into the ER, and reducing the overload of misfolded proteins.⁶ eIF2 α phosphorylation also triggers the specific translation of activating transcription factor 4 (ATF4), which is essential for the upregulation of different foldases and the regulation of the redox and metabolic status of the cell.⁷ Under prolonged ER stress, ATF4 also controls the expression of pro-apoptotic components such as CCAAT/enhancer-binding protein (C/EBP) (CHOP)/GADD153 and several

¹Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; ²Millennium Nucleus for Regenerative Biology, Faculty of Biology, P. Catholic University of Chile, Santiago, Chile; ³Center for Molecular Studies of the Cell, Institute of Biomedical Sciences, University of Chile, Santiago, Chile; ⁴Department of Molecular Biology, Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA; ⁵Neurounion Biomedical Foundation, Santiago, Chile and ⁶Department of Immunology and Infectious diseases, Harvard School of Public Health, Boston, MA, USA

*Corresponding author: C Hetz, Institute of Biomedical Sciences, University of Chile, Independencia 1027, PO BOX 70086, Santiago, Chile. Tel: + 56 2 9786506; Fax: + 56 2 9786871; E-mail: chetz@med.uchile.cl; Website: <http://ecb-icbm.med.uchile.cl/> and Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Av, Boston, MA 02446, USA. E-mail: chetz@hsph.harvard.edu or FA Court, Department of Physiology, Faculty of Biology, P. Universidad Católica de Chile, Av. B. O'Higgins 340/Casilla 114-D, Santiago 8331150, Chile. Tel: + 56 2 6862899; Fax: + 56 2 3541850; E-mail: fcourt@bio.puc.cl

Keywords: spinal cord injury; unfolded protein response; endoplasmic reticulum stress; XBP1; motor dysfunction

Abbreviations: ER, endoplasmic reticulum; UPR, unfolded protein response; SCI, spinal cord injury; ATF4, activating transcription factor 4; XBP1, X-box-binding protein 1; XBP1s, spliced XBP1; IRE1, inositol-requiring enzyme-1; PERK, PKR-like endoplasmic reticulum kinase; CHOP, CCAAT/enhancer-binding protein (C/EBP); eIF2 α , eukaryotic translation initiation factor 2A; BiP, binding immunoglobulin protein; BMS, Basso Mouse Scale; JNK, c-Jun N-terminal kinases; AAV, Adeno-associated virus; GFP, green fluorescent protein; GFAP, glial fibrillary acidic protein; NeuN, neuronal nuclei; Olig2, oligodendrocyte transcription factor 2; Cd11b, cluster of differentiation 11b

Received 04.1.12; accepted 05.1.12; Edited by A Verkhratsky

BCL-2 family members, including BCL-2, BIM, and PUMA, among others.³

Correlative studies indicate that markers of ER stress are observed in different models of SCI triggered by trauma (by contusion and hemisection) and ischemia.^{8–12} Using a contusion model, ER stress responses were observed in the damaged zone, including XBP1 mRNA splicing, in addition to the induction of CHOP and the ER chaperone BiP.¹⁰ Neuronal cells presented a fast and transient activation of UPR markers, whereas oligodendrocytes and astroglia showed sustained activation for several days.¹³ Interestingly, signs of ER stress were also detected at some distance from the injury site,⁸ suggesting a spread of the pathological stress process. Similarly, damage to the spinal cord by transient ischemia correlates with increased ER stress levels.^{12,14} A recent study indicated that deletion of *chop* enhances motor recovery after moderate levels of SCI induced by contusion,¹³ whereas CHOP deficiency did not have any effect under conditions of severe SCI.¹⁵ As CHOP expression is one of dozens downstream targets of the UPR,⁵ and the ATF4/CHOP pathway is activated by a variety of non-ER stress-related stimuli including DNA damage,¹⁶ oxidative stress,¹⁷ metabolic changes,¹⁸ inflammation, among other effects,¹⁹ direct manipulation of proximal UPR components is required to directly define the contribution of ER stress to SCI.

In this study, we confirm a massive and early upregulation of key ER stress markers in the injury zone after spinal cord hemisection, including a rapid activation of XBP1 and ATF4, in

addition to other important UPR downstream target genes. To address the possible impact of ER stress in the functional recovery after experimental SCI, we analyzed the susceptibility of ATF4- and XBP1-deficient mice to experimental SCI. Remarkably, both mouse models presented significant impairment of locomotor recovery after SCI compared with wild-type animals. These effects were associated with drastic changes at the level of oligodendrocyte number, microglia activation, inflammation markers, and axonal degeneration. Furthermore, treatment of wild-type mice with Adeno-associated viruses (AAV2) to deliver an active form of XBP1 locally into the spinal cord enhanced fine locomotor movements and increased oligodendrocyte content in the injury zone. Overall, our results indicate a detrimental impact of ER stress in SCI, identifying an unanticipated signaling target to treat this pathological condition affecting motor and sensory function.

Results

Early and sustained activation of the UPR after spinal cord hemisection. To monitor the occurrence of ER stress after SCI, we first validated the possible activation of UPR components in wild-type mice after spinal cord hemisection. A significant and progressive upregulation of XBP1 mRNA splicing was detected by RT-PCR 6 h after SCI in the injured region, and this change was sustained for several days (Figure 1a). We also observed a significant increase in XBP1 mRNA splicing in rostral regions far from the injury zone




Figure 1 UPR activation after spinal cord hemisection. (a) Wild-type mice were spinal cord-hemisectioned (H) or sham-operated (S) at the T12 vertebral level. 0.25 (6 h), 1, 3, 7, and 14 days after the surgical procedure, tissue from the operated region of the spinal cord was extracted and processed to measure spliced *Xbp1* (*Xbp1s*) mRNA levels by RT-PCR. *Actin* mRNA was used for normalization. (b) The same procedure was used to study *Xbp1* mRNA splicing at 3 and 6 h after SCI at the injured region (media) and at a distance from the injury site (rostral) (lower panel). *Xbp1s* levels were quantified and normalized using *actin* mRNA levels. (c) ATF4 protein levels were measured by western blot and semiquantified by normalizing with HSP90 protein levels. Blot and graph at 6 h after sham or hemisection from rostral (R), operated (M) and caudal (C) regions are shown. (d) *bip* and *chop* mRNA levels were quantified at the indicated times after damage by real-time PCR. (e) BIM protein levels at 6 h after SCI were measured by western blot. Protein levels were normalized with HSP90 levels and then normalized to the sham-operated condition. Mean \pm S.E.M. * $P < 0.05$; ** $P < 0.005$; Student's *t*-test; $n = 3$ animals per group for protein and mRNA analysis

(Figure 1b). Similarly, we found a significant increase in ATF4 protein levels 6 h after SCI in the injury site, in addition to distant regions of the spinal cord (Figure 1c). These changes were observed as early as 1 h after SCI (Supplementary Figure S1A). In agreement with these findings, we detected a sustained upregulation of classical UPR-target genes after SCI, including *bip* and *chop* (Figure 1d). In addition, we detected the upregulation of additional markers including BIM (Figure 1e), a pro-apoptotic BCL-2 family member modulated by ER stress,²⁰ and increased accumulation of polyubiquitinated proteins (Supplementary Figure S1B) after SCI. In summary, we were able to confirm previous findings indicating an early and sustained activation of the UPR after SCI, reinforcing the idea that protein-folding stress is a major cellular reaction under this condition.

ATF4 and XBP1 deficiency attenuates locomotor recovery after SCI. Activation of the UPR has two paradoxical consequences, adaptation to stress, improving cell survival, or the induction of apoptosis programs to eliminate the chronically damaged cell. To determine the possible functional role of proximal UPR signaling components in locomotor recovery after SCI, we subjected ATF4 knockout mice (*atf4*^{-/-}) and littermate controls to spinal cord hemisection. Analysis of locomotor activity using the Basso Mouse Scale (BMS) open field test²¹ revealed a delayed and reduced recovery of *atf4*^{-/-} mice when compared with hemisected wild-type mice (Figure 2a left panel). A similar result was obtained in the BMS subscore (Figure 2a right panel), which can detect differences in the fine details of locomotion that may not be apparent in the overall BMS score.²¹ No differences in locomotor capacity were observed between non-injured control and *atf4*^{-/-} mice by BMS or by monitoring rotarod performance (Figure 2a and

Supplementary Figure S2A), indicating that basal locomotor capacity is not compromised in *atf4*^{-/-} mice.

Under ER stress conditions, ATF4 and XBP1 have distinct effects on ER homeostasis because of the transcriptional regulation of differential subsets of target genes.²² As ATF4 is also activated by many processes that are not related to ER stress,¹⁹ we decided to further analyze the possible contribution of the UPR in SCI with a direct genetic manipulation. We evaluated the role of XBP1, which is one of the key components of the UPR and represents the most conserved ER stress signaling branch in evolution.² We recently generated a viable conditional knockout mouse model to delete *xbp1* in the nervous system using the Nestin promoter to express Cre (*XBP1*^{Nes-/-}), which do not present basal motor phenotypes.²³ Nestin-Cre system is predicted to induce deletion of oligodendrocytes and astrocytes, in addition to neurons.²⁴ Remarkably, *XBP1*^{Nes-/-} animals showed a marked reduction in locomotor recovery after SCI by both the BMS score and subscore analysis (Figure 2b). Together, the side-by-side comparison of these two independent UPR knockout mice revealed a clear functional role for ER stress in SCI.

Enhanced axonal degeneration and altered cellular environment in ATF4-deficient mice after SCI. We then evaluated the impact of ATF4 deficiency on the cellular alterations classically associated with SCI. In agreement with the negative impact of ATF4 deficiency on locomotor recovery after SCI, *atf4*^{-/-} mice presented fewer axons with normal morphology after SCI compared with control mice, as measured 2 mm caudal to the injury zone in toluidine blue-stained tissue (Figure 3a). No differences were observed in axonal density in *atf4*^{-/-} on the contralateral, non-injured side (Figure 3a). As a control,




Figure 2 Role for UPR in locomotor recovery after SCI. (a) *atf4*^{+/+} and *atf4*^{-/-} mice were hemisected at the T12 vertebral level. Their locomotion recovery pattern was monitored before (0 day) and after spinal cord hemisection using the BMS open-field test to determine their locomotor capabilities (left plot). The BMS subscore was quantified to assess locomotor recovery of finer movements (right plot). (b) The same as in (a), but comparing XBP1^{WT} with XBP1^{Nes-/-} mice. Mean \pm S.E.M. Statistical differences were analyzed by a two-way repeated-measures ANOVA followed by Bonferroni's *post hoc* test; *P*-values for SCI group comparison are indicated in the graph; *n* = 8 animals per group




Figure 3 Altered cellular environment in ATF4-deficient mice after SCI. (a) *atf4*^{+/+} and *atf4*^{-/-} mice were spinal cord-hemisectioned or sham-operated at the T12 vertebral level. At 14 days after surgery, spinal cord tissue was stained with toluidine blue to study axonal integrity (left panel). Intact axons from corticospinal tracts were quantified and expressed as axonal density values (right panel). (b) Spinal cord tissue from hemisectioned *atf4*^{+/+} and *atf4*^{-/-} mice were longitudinally sectioned to analyze the injury size by eriochrome/cyanine myelin staining. Transversal injury length was measured from the edge of the spinal cord to the midline as shown by the red-dotted line. (c) *atf4*^{+/+} and *atf4*^{-/-} mice were spinal cord-hemisectioned or sham-operated at the T12 vertebral level. At 5 days after surgery, spinal cord tissue processed for immunofluorescence for Olig2, to study oligodendrocytes and its progenitors (red); nuclei were counterstained using Hoechst (blue). Olig2-positive particles co-localizing with Hoechst were quantified every 50 μm starting at the injury site. (d) The same procedure as (c), but total Olig2/Hoechst-positive particles were quantified in a semicircular area of 300 μm radius surrounding the injury zone at 5 and 14 days post-surgery (DPS). Mean ± S.E.M. **P* < 0.05; Student's *t*-test; *n* = 3 animals per group. Scale bars, 20 μm in (a), 200 μm in (b), and 100 μm in (c). Bars indicate S.E.M.

we performed eriochrome/cyanine staining to monitor the extent of the mechanical damage in both wild-type and *atf4*^{-/-} mice, which was virtually identical (Figure 3b), also indicating that the surgery protocol was highly reproducible.

In addition to axonal degeneration, many different cellular processes are triggered by SCI, and involve multiple cell types. To define the impact of the UPR on the cellular environment in the injury zone of *atf4*^{-/-} mice, we monitored glial reactions 5 and 14 days after surgery, at the beginning of the locomotor recovery phase according to the BMS score (Figure 2). Increased accumulation of oligodendrocytes was observed in the area surrounding the injury zone of wild-type mice, as monitored by counting the number of olig2-positive cells by immunofluorescence (Figures 3c and d and Supplementary Figure S2B). This increase was ablated in *atf4*^{-/-} mice (Figure 3c). No significant differences were observed in the total number of neurons in the injury area by neuronal nuclei (NeuN) staining in either

control or *atf4*^{-/-} mice after 14 days of spinal cord hemisection (Supplementary Figure S2C).

We also monitored the reaction of microglia and astrocytes after genetically targeting ATF4. Activation of microglia was assessed using Cd11b staining. The classical microglial reaction observed after SCI was drastically reduced in *atf4*^{-/-} mice 5 days after SCI (Figure 4a). In sharp contrast, analysis of astrocyte distribution by glial fibrillary acidic protein (GFAP) immunostaining did not reveal differences between control and *atf4*^{-/-} mice at 5 or 14 days after SCI (Figure 4b and Supplementary Figure S2D). Cell density was assessed by quantifying the number of cell nuclei after Hoechst staining, which possibly represents cellular infiltration and proliferation of macrophages. This measurement was also enhanced in *atf4*^{-/-} mice after SCI (Supplementary Figure S2E). We also monitored the levels of several pro-inflammatory cytokines that are induced upon SCI including IL-1β, TNFα and IL-6. Real-time PCR analysis revealed an induction of these three cytokines in the spinal cord area




Figure 4 Altered inflammatory response in UPR-deficient mice after SCI. (a) *atf4*^{+/+} and *atf4*^{-/-} mice were spinal cord-hemisected or sham-operated at the T12 vertebral level. At 5 days after surgery, spinal cord tissue was extracted and processed for immunofluorescence for the microglial marker Cd11b at the injury zone (left panel). The density for Cd11b staining was quantified at the injured zone delimited with a dotted line (right plot) at 5 and 14 days post-surgery (PDS). (b) Activated astrocytes were studied by GFAP immunostaining. GFAP-positive label surrounding the injury zone was quantified every 50 μ m from the injury (right panel). (c) Inflammatory cytokines were analyzed from injured spinal cord tissue of *atf4*^{+/+} and *atf4*^{-/-} mice by real-time PCR 6 h after surgery (HPS). Mean \pm S.E.M. * P < 0.05; ** P < 0.005; Student's *t*-test; n = 3 animals per group. Scale bars, 300 μ m in (a) and 20 μ m in (b)

surrounding the injury zone (Figure 4c). A fivefold increase in IL-6 mRNA levels was observed in *atf4*^{-/-} mice 6 h after hemisection when compared with *atf4*^{+/+} mice (Figure 4c). TNF α levels were slightly decreased in *atf4*^{-/-}, whereas IL-1 β was not altered (Figure 4c). Taken together, our results indicate that ATF4 expression has a broad impact on the cellular and functional alterations observed after SCI.

XBP1s gene transfer into the SCI site enhances locomotor recovery. Our studies using XBP1-deficient animals indicate that the UPR has a functional role in alleviating ER stress in SCI. To test the possible therapeutic impact of further enhancing UPR responses after SCI, we developed a gain of function approach to artificially activate the UPR. We generated serotype 2 AAV-based vector to locally deliver the spliced form of XBP1 into the damaged area of the spinal cord. The vector was bicistronic and expressed green fluorescent protein (GFP) to monitor efficiency of transduction. We performed spinal cord hemisection and immediately delivered 2 μ l (10¹² DRP/ml) of AAV2, expressing either GFP alone or the XBP1s transgene into the injury zone. This strategy leads to a local and partial transduction of cells closely surrounding the injury site (Figure 5a). Although the area transduced by AAV was small, we observed a slight, but significant, improvement of locomotor performance after 28 days of SCI in animals injected with AAV2-XBP1s when compared with animals injected with the control virus (Figure 5b). Furthermore, improvement of locomotor performance was evident when

the BMS subscore was analyzed, which reveals finer aspects of locomotor function, observing a significant difference in the locomotor recovery of mice injected with XBP1s AAVs between 14 and 35 days after SCI (Figure 5c and Supplementary Figure S3a). The late effects of AAV2-mediated delivery of XBP1s transgene are consistent with the reported delay of around 7–14 days for gene expression after AAV transduction.^{25,26} Most of the cells transduced with AAV in the spinal cord were neurons and oligodendrocytes, as predicted for the serotype 2 of the viral particles (Figure 5d and Supplementary Figure S3a). Global analysis of cellularity in the injury zone by Hoechst staining indicated a reduction of cellular density after delivering XBP1s-expressing AAVs (Figures 5e and g). In addition, the accumulation of Olig2-positive cells was significantly increased in the injury zone of AAV-XBP1s-treated mice when compared with mice injected with control viruses (Figures 5f and g). In summary, these results suggest that although the pathway is already activated in SCI, forced expression of active XBP1s locally into the spinal cord can still improve locomotor performance after experimental SCI.

Discussion

SCI is a major cause of locomotor impairment and paralysis in the world. However, the molecular events underlying the cellular and functional alterations associated with SCI are not fully understood. Identifying primary signaling events initiated by SCI is essential for future therapeutic interventions aiming




Figure 5 *Xbp1s* gene transfer with AAVs enhances locomotor recovery after SCI. Wild-type mice were hemisectioned at the T12 vertebral level and immediately injected into the injury site with 2 μ l (10^{12} DRP/ml) of AAV-GFP or AAV-Xbp1s/GFP. (a) Transduction levels were analyzed 35 days after injection by GFP expression (green), immunolabelled with an Olig2 antibody (red) and counterstained with Hoechst (blue) in the AAV-Xbp1s/GFP injections. (b) Locomotion recovery pattern was monitored before (0 day), and after spinal cord hemisection and viral transduction with AAV-GFP or AAV Xbp1s/GFP, using the BMS open-field test. (c) In the same groups, the BMS subscore was quantified to assess locomotor recovery of finer movements. (d) Neuronal-specific GFP transduction was confirmed by NeuN immunostaining (red) of spinal cord tissue injected with AAV Xbp1s/GFP (in green); nuclei were counterstained using Hoechst (blue). (e) Nuclear density in the injured region was analyzed by averaging Hoechst-positive nuclei intensity from eight mice for each condition and displayed as a surface plot. The Z axis represents average intensity in a pseudo-colored map. (f) Using the same approach as in (e), Olig2-positive cell density was studied in AAV-GFP or AAV Xbp1s/GFP-injected mice. (g) To quantitatively compare cellular density profiles, intensity plots of Hoechst- or Olig2-stained spinal cords from (e) and (f) were thresholded at a fixed level (red arrowhead for Hoechst and purple arrowhead for Olig2 in the color map shown in (e)), and the resulting positive area was measured and plotted. Mean \pm S.E.M. * $P < 0.05$. Two-way repeated-measures ANOVA followed by Bonferroni's *post hoc* test for panels (b) and (c); $n = 8$ animals per group. Student's *t*-test for panel (g); $n = 8$ animals per group. Scale bars, 300 μ m in (a), 20 μ m in (d), and 300 μ m in (e) and (f)

to (i) restore the locomotor capacity of the affected individual or to (ii) attenuate the pathological events associated with spinal cord damage. Recent studies indicate that ER stress is an early tissue reaction after SCI in different models, including mechanical trauma and hypoxia.^{8,10–13,27} Here we show a fast activation of a range of UPR responses after SCI, including the expression of the proximal components ATF4 and XBP1, major transcription factors governing this pathway, in addition to the upregulation of downstream target genes. Remarkably, UPR activation was also observed in regions distant from the primary injury zone, suggesting the activation of a broad ER stress response in the spinal cord after damage. Interestingly, a recent report in cancer models suggested that under ER stress conditions, a transmissible signal related to pro-inflammatory events propagates the protein-folding stress response to the surrounding tissue,²⁸ a phenomena that may also operate after SCI. Altered axonal trafficking due to spinal cord hemisection may also contribute to the activation of the UPR at distal regions because of a traffic jam in vesicular transport. We also analyzed available microarray data sets of SCI-contusion models in mice (Gene Expression Omnibus, NCBI) that confirmed a strong induction of sustained ER stress responses (Supplementary Figure S4).

Using genetic manipulation of the UPR, we demonstrated a functional role of this stress pathway in locomotor recovery

after SCI. A recent study described the contribution of the pro-apoptotic transcription factor CHOP in models of mild SCI.¹³ CHOP deficiency enhanced motor recovery after SCI, correlating with enhanced content of oligodendrocyte and white-matter sparing.¹³ CHOP is one of a large group of downstream targets of proximal UPR transcription factors that controls the expression of many late-phase genes related to apoptosis and protein synthesis.⁵ In contrast, in models of severe SCI, ablation of *chop* did not have an effect on motor recovery.¹⁵ CHOP expression is mostly controlled by the eIF2 α /ATF4 signaling branch, which is activated not only by the UPR sensor PERK but also by the kinases GCN2, HRI, and PKR² that are non-ER stress-dependent. Therefore, our genetic studies with XBP1-deficient animals, and the development of an AAV-XBP1s gene therapy approach, represent the first direct proof for an involvement of the ER stress in SCI.

We speculate that the UPR may enhance neuronal plasticity events and functional recovery during the recovery phase after SCI related to neuronal functionality (cell autonomous events). Axonal degeneration was enhanced in *atf4*^{-/-} mice, correlating with impaired motor recovery after experimental SCI. Axonal degeneration might be an indicator of oligodendrocyte dysfunction, having a direct impact on locomotor recovery. Consistent with these findings, the accumulation of oligodendrocytes near the injury zone was

reduced after deleting *atf4* and enhanced after overexpressing XBP1s. Cell-type-dependent ER stress responses have been previously observed in SCI models.^{10,12,13} It has been described that the presence of NG2-positive cells in the injury zone is associated with the stabilization and regeneration of dystrophic axons after SCI.²⁹ In addition, increased oligodendrocyte number may also enhance the functional recovery of spared axons that were not directly ruptured and altered by the pro-inflammatory/oxidative environment. Remarkably, Keirstead *et al.*³⁰ reported a functional improvement of locomotion when human patients were transplanted with human embryonic cell-derived oligodendrocyte progenitor cells. We also observed differential microglial activation 5 days after injury in *atf4*^{-/-} mice, which may contribute to the attenuated motor recovery in these mice after SCI. Interestingly, activated microglia has been suggested to attenuate oligodendrocyte precursor cell proliferation *in vitro*,³¹ providing a possible link between both cell type responses following SCI. The differences in cytokine levels observed in *atf4*^{-/-} mice could alter different cellular processes including proliferation, differentiation, and cell death associated with SCI.²⁹ On the basis of our observations, we speculate that the UPR may be involved in controlling oligodendrocyte-dependent protective functions in the injury site that could contribute to locomotion recovery after SCI.

ER stress is proposed to be a relevant factor in the pathogenesis of many neurodegenerative diseases involving abnormal protein folding.¹ We have previously investigated the impact of the UPR in neurodegenerative diseases. Ablation of XBP1 in a model of amyotrophic lateral sclerosis (ALS) has a contrasting effect on spinal cord from the results presented here in SCI models. Despite expectations that XBP1 deficiency would enhance the pathogenesis of mutant SOD1-mediated ALS, a dramatic neuroprotection was observed owing to an enhanced clearance of mutant SOD1 aggregates by macroautophagy.³² In sharp contrast, PERK haplo-insufficiency enhances ALS progression.³³ Besides, XBP1 deficiency did not affect prion misfolding or pathogenesis *in vivo*.²³ Other reports indicate that XBP1 has a protective effect in animal models of Parkinson's disease, Alzheimer's disease, and autosomal dominant retinitis pigmentosa.¹ ATF4 deficiency results in resistance to oxidative stress in models of brain ischemia.^{34,35} PERK/eIF2 α signaling has protective effects on axonal remyelination in models of experimental autoimmune encephalomyelitis, possibly because of the control of oligodendrocyte viability and function.³³ Together with the current study, these reports suggest an intriguing scenario where specific UPR signaling branches may have distinct and contrasting consequence depending on the nature of the pathological stimuli.

A variety of mechanisms underlying modifications of ER homeostasis may take place in specific disease contexts, and could include inhibition of ER-associated degradation, altered vesicular trafficking, and altered protein-folding networks among others.¹ In addition, alterations in lipid, cholesterol, or calcium metabolism may also affect ER function in many diseases affecting the nervous system. Interestingly, the physiological role of the UPR has been mostly attributed to maintaining an efficient rate of protein synthesis and secretion in specialized secretory cells including B lymphocytes,

pancreatic β cells, salivary glands, and many others.⁵ Neuronal and glial populations with higher secretory requirements might display increased sensitivity to genetic and environmental factors that disrupt ER function. In this context, oligodendrocytes and neuropeptide-secretory neurons are of particular relevance for future studies in order to uncover the mechanisms underlying the impact of the UPR in SCI. In fact, correlative studies suggest that the protection of valproate^{11,36} or sodium 4-phenylbutyrate¹⁴ against SCI models is associated with attenuated levels of ER stress markers. The partial improvement obtained after XBP1s gene transfer over a wild-type condition where the UPR is already activated suggests that locomotor improvements can be achieved with treatments of days after damage (considering the delay of > 1 week for gene expression after AAV gene transfer). The improvements in locomotor recovery observed in the gene therapy experiments may be actually important in the context of a patient that could progress from a state of full paralysis to gaining partial control of some movements, having significant impact on the quality of life. Overall, this study together with recent findings, identifies the UPR pathway as a potential target to treat SCI. Importantly, the use of small molecules or gene therapy strategies to attenuate ER stress or artificially engage UPR responses may have a beneficial impact to attenuate tissue damage and enhance locomotor recovery in conditions affecting the function of the spinal cord.

Materials and Methods

Experimental animals and surgical procedures. Animals of 8 weeks of age, with body weight between 20 and 25 g were used in this study. ATF4 knockout mice and XBP-1 conditional knockout mice were previously described.^{23,37} All animals were used on a pure C57bl6 genetic background. Mice were anesthetized with a single dose of 330 mg/kg of 2-2-2 Tribromoethanol (Sigma, St. Louis, MO, USA) intraperitoneally. Then, the dorsal zone of the spinal cord was incised along the midline; the T12 vertebra was laminectomized to expose the spinal cord. At this level, the spinal cord was hemitransected on the right side using a vannas micro scissor (RS-5658, ROBOZ, Gaithersburg, MD, USA). Sham animals include the complete surgical procedure without hemitranssection of the spine. During recovery, mice were placed in a temperature-controlled chamber. At different days after surgery, animals were euthanized by an overdose of anesthesia. Surgical interventions and animal care follows the Institutional Review Board's Animal Care of the University of Chile (CBA # 0305 FMUCH).

Western blot analysis of spinal cord extracts. A 5-mm spinal cord tissue containing the hemitransected region (medial), in addition to rostral and caudal regions of the same size, were collected and homogenized in 0.1 M phosphate buffered saline (pH 7.4) containing a protease inhibitor cocktail (PIC, Roche, Basel, Switzerland). Half of the homogenized volume was used for protein extraction and the other half was used for RNA extraction (see below). The first volume was re-homogenized by sonication in RIPA buffer (20 mM Tris at pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, and 0.5% Triton X-100) plus PIC and then samples were analyzed by SDS-PAGE. The following antibodies and dilutions were used: anti-HSP90, 1 : 5000 (sc-7947, H114, Santa Cruz, Santa Cruz, CA, USA), anti-ATF4, 1 : 3000 (sc-200, C-20, Santa Cruz), anti-BIM, 1 : 2000 (sc-8267, M-20, Santa Cruz), and anti-ubiquitin 1 : 1000 (sc-8017, P4D1, Santa Cruz).

RNA extraction and RT-PCR. Total RNA was prepared from spinal cord tissue previously homogenized in saline phosphate buffer (PBS) using TRIzol (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized by iScript cDNA Synthesis (Bio-Rad, Hercules, CA, USA) using random primers p(dN)6 (Roche, Basel, Switzerland). Quantitative real-time PCR was performed in an ABI PRISM7700 system (Applied Biosystems, Foster City, CA, USA) employing SYBRgreen fluorescent reagent (Applied Biosystems) using the following primers: *bip* forward 5'-TCATCGGACGCACTTGGAA-3'; *bip* reverse 5'-CAACCACCTTGATGGC

AAGA-3'; chop forward 5'-TGGAGAGCGAGGGCTTTG-3'; chop reverse 5'-GTCCCTAGCTTGCTGACAGA-3'; *actin* forward 5'-CTCAGGAGGAGCAATGATCTTGAT-3'; *actin* reverse 5'-TACCACCATGTACCAGGCA-3'; *IL-1 β* forward 5'-CAACCAACAAGTGATATTCTCCATG-3'; *IL-1 β* reverse 5'-GATCCACACTCTCCAGCTGCA-3'; *IL-6* forward 5'-GAGGATACCCTCCCAACAGACC-3'; *IL-6* reverse, 5'-AAGTGATCATCGTTGTCATACA-3'; and *TNF α* forward 5'-CATCTTCTCAAATTTCGAGTGACAA-3'; *TNF α* reverse 5'-TGGGAGTAGACAAGGTACAACCC-3'. XBP1 mRNA splicing assay was performed as previously described using PstI digestion of PCR products using the following primers: mXBP1.3S (5'-AAA CAGAGTAGCAGCGCAGACTGC-3') and mXBP1.2AS: (5'-GGATCTCTAAACTAG AGGCTTGGTG-3').

Locomotor function. Locomotor recovery was evaluated in an open-field test using the nine-point Basso Mouse Scale (BMS).²¹ The BMS analysis of hindlimb movements and coordination for lateral hemisection SCI model was performed by two independent investigators blinded to the experimental condition as described before.³⁸ Our laboratory was certified during the 2009 Spinal Cord Injury Research Training Program at Ohio State University, USA, to perform BMS assays.

BMS analysis involved measuring the following parameters and scores: (0) no ankle movement; (1) slight ankle movement; (2) extensive ankle movement; (3) plantar placing of the paw with or without weight support, or occasional, frequent or consistent dorsal stepping but no plantar stepping; (4) occasional plantar stepping; (5) frequent or consistent plantar stepping, no coordination or frequent, or consistent plantar stepping, some coordination, paws rotated at initial contact and lift off; (6) frequent or consistent plantar stepping, some coordination, paws parallel at initial contact, or frequent or consistent plantar stepping, mostly coordinated, paws rotated at initial contact and lift off; (7) frequent or consistent plantar stepping, mostly coordinated, paws parallel at initial contact and rotated at lift off, or frequent or consistent plantar stepping, mostly coordinated, paws parallel at initial contact and lift off, and severe trunk instability; (8) frequent or consistent plantar stepping, mostly coordinated, paws parallel at initial contact and lift off, and mild trunk instability, or frequent or consistent plantar stepping, mostly coordinated, paws parallel at initial contact and lift off, and normal trunk stability, and tail down or up and down; (9) frequent or consistent plantar stepping, mostly coordinated, paws parallel at initial contact and lift off, and normal trunk stability and tail always up. In general, the score for individual hindlimb ranged from 0 to 5 points (parameters that do not involve coordination); and parameters involving the use of both hind limbs reached between 6 and 9 points. The 11-point BMS subscore was used to evaluate finer aspects of locomotor capacity, which are not revealed by the BMS.²¹ BMS subscore included the following interval of scores: plantar stepping (0–2); coordination (0–2); paw position (0–4); trunk stability (0–2); and tail position (0–1).

To control the surgery, the following criteria of exclusion were employed: (i) at 1 day after surgery, mice with < 5 points in its contralateral hindlimb were excluded for the study (around 1 of 16 animals). (ii) If the BMS score for the ipsilateral hindlimb was > 1 point at 1 day after surgery, the mouse was excluded for the study (around 1 of 16 animals). The final score is presented as mean \pm S.E.M.

Histological analysis. At 5 or 14 days after surgery, mice were perfused transcardially with 4% paraformaldehyde in 0.1 M PBS. A 5-mm region of the spinal cord containing the lesion site was removed and post-fixed for 3 h in 4% paraformaldehyde. The spinal tissue was subjected to a sucrose gradient (5, 10, and 30% sucrose in PBS), cryoprotected with optimal cutting temperature compound (Tissue-Tek, Alphen aan den Rijn, The Netherlands), and fast frozen using liquid nitrogen. The tissue was longitudinally sectioned (5 μ m-thick slices) using a cryostat microtome (Leica, Nussloch, Germany). Sections were immunostained using antibodies anti-Cd11b, 1:100 (MCA74G, Serotec, Morphosys, Oxford, UK), NeuN 1:300 (MAB377, Millipore Bioscience Research Reagents, Billerica, MA, USA), anti-Olig-2 1:200 (ab9610, Millipore Bioscience Research Reagents), and GFAP 1:1000 (N1506, Dako, Glostrup, Denmark). Tissue sections were viewed with an Olympus IX71 microscope (Olympus, Center Valley, PA, USA) and images were captured using a QImaging QICAM Fast 1394 camera (Surrey, BC, Canada). Olig2-positive cells surrounding the injury zone were analyzed using a matrix of 50 μ m-separated concentric semicircles. GFAP staining intensity was calculated by creating an integrated intensity profile along the spinal cord with its center located in the injury site. Neuronal numbers were assessed by counting NeuN-positive cells in the spinal tissue, excluding the mechanically injured region. Cd11b-positive cells were determined in the region surrounding the mechanically injured zone. Longitudinal SC slices were also used for eriochrome/cyanine staining. Slices were imaged using an OLYMPUS CX31 microscope fitted

with a CCD camera. All quantifications were done using ImageJ software (NIH, Bethesda, MD, USA). For EM analyses, spinal cord tissue was processed as described.³⁹ Resin slices measuring 1 μ m were cut and toluidine blue stained as described.³⁹ Slices were imaged using an Olympus IX71 microscope fitted with a QImaging QICAM Fast 1394 camera.

AAV production and injection of viral particles into the spinal cord. The whole Xbp-1 expression cassette was excised from pcDNA3XBP-1S as a MfeI/SphI fragment and inserted into a proviral plasmid pAAVsp70 containing AAV2-inverted terminal repeats (ITRs). The vector is bicistronic and carries a GFP expression cassette that serves as a fluorescent marker for transduced cells. Recombinant AAV2.XBP1S was produced by triple transfection of 293 cells using a rep/cap plasmid and pHelper (Stratagene, La Jolla, CA, USA) and purified by column affinity chromatography, as previously described.⁴⁰ Viral titers were determined using a real-time TaqMan PCR assay (ABI Prism 7700; Applied Biosystems) with primers that were specific for the BGH polyA sequence. For animal treatment, 2 μ l of AAVs (10¹² DRP/ml) were injected slowly over the injury site, right after performing the hemisection using a 10- μ l Hamilton syringe fitted with a 34G needle. We confirmed the expression of XBP1s protein and upregulation of the target genes EDEM1, ERp72, and Sec61 after the stereotaxis injection of AAV-XBP1 into the brain followed by real time PCR analysis (not shown).

Statistical analysis. Data are shown as mean \pm S.E.M. Statistical analyses were performed by using Student's *t* test or two-way repeated-measures ANOVA, followed by a Bonferroni *post hoc* test for multiple comparisons.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. We thank Monica Perez for excellent EM processing and Alejandra Catenaccio for technical assistance. This work was primarily supported by a North American Spine Society (NASS) Award. We also thank for the financial support from FONDECYT No. 1100176, FONDAP No. 15010006, Millennium Institute No. P09-015-F, Alzheimer's Association, Muscular Dystrophy Association, The Michael J. Fox Foundation for Parkinson's Research, and ICGEB (to CH). CONICYT Doctoral fellowship (EC) and FONDECYT No. 1110987, Millennium Nucleus No. P07-011-F (FC).

- Matus S, Glimcher LH, Hetz C. Protein folding stress in neurodegenerative diseases: a glimpse into the ER. *Curr Opin Cell Biol* 2011; **23**: 239–252.
- Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. *Nat Rev Mol Cell Biol* 2012; **13**: 1–14.
- Woehlbier U, Hetz C. Modulating stress responses by the UPORosome: a matter of life and death. *Trends Biochem Sci* 2011; **36**: 329–337.
- Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol* 2007; **8**: 519–529.
- Hetz C, Martinon F, Rodriguez D, Glimcher LH. The unfolded protein response: integrating stress signals through the stress sensor IRE1 α . *Physiol Rev* 2011; **91**: 1219–1243.
- Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. *Nature* 1999; **397**: 271–274.
- Schroder M, Kaufman RJ. The mammalian unfolded protein response. *Annu Rev Biochem* 2005; **74**: 739–789.
- Aufenberg C, Wenkel S, Mautes A, Paschen W. Spinal cord trauma activates processing of xbp1 mRNA indicative of endoplasmic reticulum dysfunction. *J Neurotrauma* 2005; **22**: 1018–1024.
- Paschen W, Aufenberg C, Hotop S, Mengesdorf T. Transient cerebral ischemia activates processing of xbp1 messenger RNA indicative of endoplasmic reticulum stress. *Blood* 2003; **23**: 449–461.
- Penas C, Guzman MS, Verdu E, Fores J, Navarro X, Casas C. Spinal cord injury induces endoplasmic reticulum stress with different cell-type dependent response. *J Neurochem* 2007; **102**: 1242–1255.
- Penas C, Verdú E, Asensio E, Guzmán-Lenis MS, Herrando-Grabulosa M, Navarro X et al. Valproate reduces CHOP levels and preserves oligodendrocytes and axons after spinal cord injury. *Neuroscience* 2011; **178**: 1–12.
- Yamauchi T, Sakurai M, Abe K, Matsumiya G, Sawa Y. Impact of the endoplasmic reticulum stress response in spinal cord after transient ischemia. *Brain Res* 2007; **1169**: 24–33.
- Ohri SS, Maddie MA, Zhao Y, Qiu MS, Hetman M, Whittemore SR. Attenuating the endoplasmic reticulum stress response improves functional recovery after spinal cord injury. *Glia* 2011; **59**: 1489–1502.

14. Mizukami T, Orihashi K, Herlambang B, Takahashi S, Hamaishi M, Okada K *et al*. Sodium 4-phenylbutyrate protects against spinal cord ischemia by inhibition of endoplasmic reticulum stress. *J Vasc Surg* 2010; **52**: 1580–1586.
15. Ohri SS, Maddie MA, Zhang YP, Shields CB, Hetman M, Whittemore SR. Deletion of the pro-apoptotic endoplasmic reticulum stress response effector CHOP does not result in improved locomotor function after severe contusive spinal cord injury. *J Neurotrauma* 2011; e-pub ahead of print 21 November 2011.
16. Luethy JD, Holbrook NJ. Activation of the gadd153 promoter by genotoxic agents: a rapid and specific response to DNA damage. *Cancer Res* 1992; **52**: 5–10.
17. Tang JR, Nakamura M, Okura T, Takata Y, Watanabe S, Yang ZH *et al*. Mechanism of oxidative stress-induced GADD153 gene expression in vascular smooth muscle cells. *Biochem Biophys Res Comm* 2002; **290**: 1255–1259.
18. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. *Cell* 2010; **140**: 900–917.
19. Ameri K, Harris AL. Activating transcription factor 4. *Int J Biochem Cell Biol* 2008; **40**: 14–21.
20. Puthalakath H, O'reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND *et al*. ER stress triggers apoptosis by activating BH3-only protein Bim. *Cell* 2007; **129**: 1337–1349.
21. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG. Basso mouse scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. *J Neurotrauma* 2006; **23**: 635–659.
22. Hetz C, Glimcher LH. Fine-tuning of the unfolded protein response: assembling the IRE1a interactome. *Mol Cell* 2009; **34**: 1–11.
23. Hetz C, Lee AH, Gonzalez-Romero D, Thielen P, Castilla J, Soto C *et al*. Unfolded protein response transcription factor XBP-1 does not influence prion replication or pathogenesis. *Proc Natl Acad Sci USA* 2008; **105**: 757–762.
24. Raasch J, Zeller N, van Loo G, Merkler D, Mildner A, Erny D *et al*. IkkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system. *Brain* 2011; **134** (Pt 4): 1184–1198.
25. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA *et al*. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. *Proc Natl Acad Sci USA* 2000; **97**: 3428–3432.
26. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. *Mol Ther* 2008; **16**: 1073–1080.
27. Hong Z, Hong H, Chen H, Wang Z, Hong D. Protective effects of erythropoietin in experimental spinal cord injury by reducing the C/EBP-homologous protein expression. *Neurol Res* 2012; **34**: 85–90.
28. Mahadevan NR, Rodvold J, Sepulveda H, Rossi S, Drew AF, Zanetti M. Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells. *Proc Natl Acad Sci U S A* 2011; **108**: 1–6.
29. Lees JR, Cross AH. A little stress is good: IFN-gamma, demyelination, and multiple sclerosis. *J Clin Invest* 2007; **117**: 297–299.
30. Keirstead HS, Nistor G, Bernal G, Totiu M, Cloutier F, Sharp K *et al*. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. *J Neurosci* 2005; **25**: 4694–4705.
31. Taylor DL, Pirianov G, Holland S, McGinnity CJ, Norman AL, Reali C *et al*. Attenuation of proliferation in oligodendrocyte precursor cells by activated microglia. *J Neurosci Res* 2010; **88**: 1632–1644.
32. Hetz C, Thielen P, Matus S, Nassif M, Court F, Kiffin R *et al*. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. *Genes Dev* 2009; **23**: 2294–2306.
33. Wang L, Popko B, Roos RP. The unfolded protein response in familial amyotrophic lateral sclerosis. *Hum Mol Genet* 2011; **20**: 1008–1015.
34. Lange PS, Chavez JC, Pinto JT, Coppola G, Sun CW, Townes TM *et al*. ATF4 is an oxidative stress-inducible, prodeath transcription factor in neurons *in vitro* and *in vivo*. *J Exp Med* 2008; **205**: 1227–1242.
35. Galehdar Z, Swan P, Fuerth B, Callaghan SM, Park DS, Cregan SP. Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA. *J Neurosci* 2010; **30**: 16938–16948.
36. Ryoo HD, Domingos PM, Kang MJ, Steller H. Unfolded protein response in a Drosophila model for retinal degeneration. *Embo J* 2007; **26**: 242–252.
37. Tanaka T, Tsujimura T, Takeda K, Sugihara A, Maekawa A, Terada N *et al*. Targeted disruption of ATF4 discloses its essential role in the formation of eye lens fibres. *Genes Cells* 1998; **3**: 801–810.
38. Boido M, Rupa R, Garbossa D, Fontanella M, Ducati A, Vercelli A. Embryonic and adult stem cells promote raphespinal axon outgrowth and improve functional outcome following spinal hemisection in mice. *Eur J Neurosci* 2009; **30**: 833–846.
39. Barrientos SA, Martinez NW, Yoo S, Jara JS, Zamorano S, Hetz C *et al*. Axonal degeneration is mediated by the mitochondrial permeability transition pore. *J Neurosci* 2011; **31**: 966–978.
40. O'Riordan CR, Lachapelle AL, Vincent KA, Wadsworth SC. Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). *J Gene Med* 2000; **2**: 444–454.



Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>

Supplementary Information accompanies the paper on Cell Death and Disease website (<http://www.nature.com/cddis>)